Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Dutoit, Valérie, Migliorini, Denis, Ranzanici, Giulia, Marinari, Eliana, Widmer, Valérie, Lobrinus, Johannes Alexander, Momjian, Shahan, Costello, Joseph, Walker, Paul R., Okada, Hideho, Weinschenk, Toni, Herold-Mende, Christel, Dietrich, Pierre-Yves
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749651/
https://ncbi.nlm.nih.gov/pubmed/29308320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1391972
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares